Ironwood Pharmaceuticals, Inc. specializes in the research, development, and commercialization of human therapeutics, primarily targeting gastrointestinal disorders. Its lead commercial product, LINZESS (linaclotide), is a guanylate cyclase-C (GC-C) agonist marketed in the United States in partnership with AbbVie, and internationally under the brand name CONSTELLA. Beyond its commercialized treatments, Ironwood maintains a clinical pipeline that includes apraglutide, a next-generation synthetic GLP-2 analog for short bowel syndrome, and other candidates like IW-3300 for visceral pain conditions. The company operates primarily in the United States but leverages strategic partnerships with companies like Astellas Pharma and AstraZeneca to distribute its therapies globally. Originally founded as Microbia, Inc. in 1998, the company rebranded to Ironwood Pharmaceuticals in 2008.
